Copernicus Group IRB
Copernicus Group IRB (part of WCG Clinical) is an independent central Institutional Review Board providing ethical and regulatory review of clinical research protocols for pharmaceutical, biotech, medical device, academic, and CRO clients across North America, delivered via a ClinSphere® technology platform and a board of nearly 200 IRB experts.
- Company typePrivate
- Founded1970
- HeadquartersCary, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Copernicus Group IRB does
Copernicus Group IRB (CG IRB), operating within the WCG Clinical family of companies, is a Cary, North Carolina-based independent Institutional Review Board (IRB) founded in 1996 with a 51-100 employee operating footprint and broader historical lineage to the 1970 founding of the Western Institutional Review Board. The organization specializes in independent ethical and regulatory review of clinical research protocols, serving as a central IRB for pharmaceutical and biotechnology sponsors, medical device developers, academic institutions and medical centers, and Contract Research Organizations (CROs). The firm claims pioneer status in the independent ethical review category, was the first central IRB to achieve AAHRPP accreditation, and maintains ISO 9001 certification across IRB services. Its review scope spans Phase I through Phase III, including rare disease, first-in-human, pediatric, social/behavioral, biologics (CAR-T, stem cells, viral vectors), and medical device studies, with a separate Institutional Biosafety Committee (IBC) review service for gene transfer and related biosafety work.
The core product is IRB review delivered through a custom board of nearly 200 IRB experts and one of the largest external clinical advisory networks, with disclosed operational metrics of less than six days for new protocol determinations and less than two days for new site determinations, processed seven days a week, twelve hours a day. The technology stack centers on the ClinSphere® suite, which integrates the eReview Manager workflow interface, IRBNet (acquired 2012), InvestigatorSpace® Training & Safety Portal, Total Enrollment and Total Feasibility tools, AIMS® analytics, eResearch Enterprise CTMS, Clinical Trial Listing Service, and the 2023-launched ClinSphere Trial IntelX™ intelligence platform. Compliance posture spans FDA 21 CFR Parts 50 and 56, HIPAA, GDPR, and Health Canada Division 5.
Revenue mechanics are professional-services fee-for-review, quote-based (no public pricing), with multi-year enterprise contracts and a single-point-of-contact account management model. Go-to-market is hybrid enterprise field sales combined with self-service digital submission via the eReview Manager portal. Marquee customers named in source material include Genentech, PPD, and a Level I Trauma Hospital's trauma research department. The 2023 rebrand from WCG to WCG Clinical reflects deliberate positioning of the firm as a clinical research services platform rather than a pure-play IRB.
Copernicus Group IRB firmographics
Firmographics- Name
- Copernicus Group IRB
- Legal name
- WCG Clinical
- Website
- https://cgirb.com
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Copernicus Group IRB (part of WCG Clinical) is an independent central Institutional Review Board providing ethical and regulatory review of clinical research protocols for pharmaceutical, biotech, medical device, academic, and CRO clients across North America, delivered via a ClinSphere® technology platform and a board of nearly 200 IRB experts.
- Ownership category
- akta.pro rank
Copernicus Group IRB industry classification
Industry- Product category
- Clinical Research Ethics Review (IRB) Services
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight) (HLAJACAG)
Keywords
Where Copernicus Group IRB is headquartered
LocationHeadquarters
- HQ city
- Cary
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Copernicus Group IRB business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- IRB Review Services: Core revenue from providing independent ethical review services for clinical research protocols. Services include protocol determinations, site determinations, and specialized review for various study types (pharmaceutical, device, biologics, pediatric, social/behavioral). Revenue is generated through service fees for review submissions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based service pricing for IRB review services |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Copernicus Group IRB product offering
Product offeringCore offering
Copernicus Group IRB (operating as WCG IRB) provides independent ethical review and human-subject protection services for clinical research studies. Its core offering is central IRB review of clinical trial protocols, supported by a custom board of nearly 200 expert reviewers, with supplemental IBC biosafety review, IRB technology platforms, and clinical trial management solutions.
Product overview
WCG offers a comprehensive platform-plus-modules architecture centered on IRB review services for clinical research. The core offering includes IRB Review (ethical review for protocols) and IBC Review (biosafety committee review), with premium IRB+ service for accelerated processing. The ClinSphere® platform serves as the central hub integrating multiple specialized solutions including eReview Manager (modern IRB workflow interface), IRBNet (submission management), AIMS® (analytics), Total Enrollment (recruitment tracking), Total Feasibility (site assessment), eResearch Enterprise CTMS (trial management), and ClinSphere Trial IntelX™ (clinical trial intelligence). Supporting services include WCG Site Network, Safety Letter Distribution, Diversity/DEI solutions, CTMS support, Financial Management, and Expanded Access support. The platform processes reviews 7 days per week with dedicated workflows for pharmaceutical, medical device, Phase I, pediatric, social/behavioral, and biologics research.
Differentiator
Problem solved
Functional benefit
Brands
- IRB+: Premium IRB service offering accelerated processing and white-glove service for studies requiring expedited ethical review
- ClinSphere eReview Manager
- IRBNet
- Total Enrollment
- Total Feasibility
- InvestigatorSpace
- Trial IntelX
- AIMS
Products and services
- IRB Review
Quantifiable outcome
- <6 days for new protocol determinations (from submission to document delivery)
- +4 more outcomes
Companies that use Copernicus Group IRB
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
Copernicus Group IRB technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Copernicus Group IRB partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Dr. Vince Clinical ResearchcorePartnership announced September 2022 to expand Phase I review services. Dr. Vince Clinical Research provides specialized expertise in Phase I/first-in-human studies, bringing former Phase I investigator experience to WCG's board review capabilities.
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
Copernicus Group IRB competitors and assessment
Company assessmentDirect peers
- Advarra: Formed from the merger of Schulman IRB and Quorum Review IRB, Advarra is the largest direct competitor to Copernicus Group IRB as an AAHRPP-accredited central IRB serving pharma, biotech, device, and academic sponsors. Both compete head-to-head on central IRB review services for multi-site clinical research.
- BRANY (Biomedical Research Alliance of New York): AAHRPP-accredited central IRB serving academic medical centers, hospitals, and sponsors. Operates a comparable independent ethical review model for multi-site clinical research and competes with WCG for protocol and site review assignments.
- Sterling IRB: Independent central IRB providing ethical review services to sponsors, CROs, and sites. Operates a similar business model focused on accelerating study start-up with AAHRPP accreditation, directly competing with WCG on protocol review.
Broad incumbents
- IQVIA: Global CRO with clinical trial technology, site networks, and increasingly integrated IRB-adjacent services. While not a central IRB, IQVIA competes for sponsor clinical-operations spend and offers workflow tooling that overlaps with WCG's ClinSphere platform.
- ICON plc: Large global CRO providing clinical research services, technology platforms, and site support across therapeutic areas. Competes with WCG for sponsor budgets on the broader clinical-trial-operations stack beyond pure IRB review.
- Charles River Laboratories: Major CRO and preclinical/clinical services provider that competes for sponsor study-start-up and trial-management budgets. While not a central IRB, its end-to-end research services overlap with the broader WCG value proposition.
- Labcorp Drug Development (formerly Covance): Global clinical research and diagnostics services organization with central laboratory capabilities and clinical trial support. Competes for clinical-operations spend and overlapping site-management and study-start-up services.
Emerging players
- Veeva Systems: Cloud software provider for life sciences with Veeva Vault CTMS, eTMF, and clinical operations suites that compete with several modules of WCG's ClinSphere platform (AIMS, eResearch CTMS). Comparable in workflow-software category rather than as an IRB.
- Medidata Solutions (Dassault Systèmes): Clinical trial technology platform offering CTMS, eCOA, randomization, and trial-design tools. Competes with WCG's clinical-operations platform modules (CTMS, feasibility, trial intelligence) for sponsor technology budgets.
Regional players
- BioMedical Research Alliance of New York (BRANY): Beyond its US IRB operations, BRANY has expanded biosafety and research compliance services regionally. While comparable in central IRB, regional academic orientation differentiates it from WCG's national sponsor focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Copernicus Group IRB social profiles
Digital presenceCopernicus Group IRB compliance and trust
Trust signalCompliance5 records
Copernicus Group IRB financial estimates
Financial estimateRevenue estimate
Valuation estimate
Copernicus Group IRB leadership team
Management profileNumber of profiles
Profiles1 record
Copernicus Group IRB funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Copernicus Group IRB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Copernicus Group IRB
What does Copernicus Group IRB do?
Copernicus Group IRB (operating as WCG IRB) provides independent ethical review and human-subject protection services for clinical research studies. Its core offering is central IRB review of clinical trial protocols, supported by a custom board of nearly 200 expert reviewers, with supplemental IBC biosafety review, IRB technology platforms, and clinical trial management solutions.
Is Copernicus Group IRB a public or private company?
Copernicus Group IRB is a private company. It is classified as unknown and is currently operating.
When was Copernicus Group IRB founded?
Copernicus Group IRB was founded in 1970. It employs 51 to 100 people.
Where is Copernicus Group IRB based?
Copernicus Group IRB is headquartered in Cary, United States, in the North America region.
How does Copernicus Group IRB make money?
One revenue line is on record: IRB Review Services.
Who are Copernicus Group IRB's main competitors?
Direct peers on record are Advarra, BRANY (Biomedical Research Alliance of New York) and Sterling IRB. Broad incumbents are IQVIA, ICON plc, Charles River Laboratories and Labcorp Drug Development (formerly Covance). Emerging players are Veeva Systems and Medidata Solutions (Dassault Systèmes). BioMedical Research Alliance of New York (BRANY) is listed as a regional player.
Does Copernicus Group IRB have an API?
No public API is recorded for Copernicus Group IRB.
What industry is Copernicus Group IRB in?
Copernicus Group IRB's product category is Clinical Research Ethics Review (IRB) Services. Its primary akta.pro industry code is HLAJACAG, Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight). Its NAICS code is 54169 and its SIC code is 8090.